What this means
This is a plan for a study that has not started recruiting people yet. It does not show whether the vaccine works or is safe.
Plain-English summary written by an AI model from the registry listing.
- Status
- Opening soon
- Who can join
- Ages 40 and over
- Where
- Not listed
The science
- Registered title
- Immunogenicity and Safety of SYS6052 in the Participants Aged 40 Years and Above
- Trial ID
- NCT07892989 ↗
- Phase
- PHASE 1 / PHASE 2
- Study type
- interventional
- Conditions
- Herpes Zoster
- What is tested
- Recombinant Zoster Vaccine (CHO cell) SYS6052, Placebo: 0.9% sodium chloride injection, Active Comparator Vaccine
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
- Ages
- 40 Years to no maximum
- Dates
- First posted Oct 23, 2026 · updated Oct 23, 2026
Registry summary
Herpes zoster is caused by the reactivation of latent varicella-zoster virus (VZV) which stays in latency after its primary infection. Immunosenescence contributes significantly to elevating morbidity associated with aging. Vaccination plays a key role in reducing the disease burden of zoster and the associated complications. We are conducting a study entitled "A Randomized, Blinded, Controlled, Phase I/II Clinical Trial to Evaluate the Safety and Immunogenicity of SYS6052 (Recombinant Herpes Zoster Vaccine (CHO Cell)) Administered to Participants Aged 40 Years and Above".